Skip to main content

Advertisement

SpringerLink
Log in

Parkinson’s disease: Medical treatment of moderate to advanced disease

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Parkinson’s disease, a common neurodegenerative disorder, results in significant morbidity 10 to 15 years after disease onset and increased mortality. Levodopa is the mainstay of therapy and provides benefit for the duration of the illness. However, within 5 years, up to 50% of individuals develop fluctuations, including dyskinesias, wearing off, and "on/off" effects. Optimal management of Parkinson’s disease patients requires careful titration of medications, with use of polypharmacy, including levodopa, dopamine agonists, catechol-O-methyltransferase inhibitors, amantadine, and anticholinergics in order to maintain good motor function and quality of life. With advancing disease, problems such as dysphagia, dysarthria, and gait and balance abnormalities occur, which are not responsive to dopaminergic medication. Due to extradopaminergic neuronal system degeneration, autonomic dysfunction can also be prominent. Recognition and management of these problems is helpful in improving quality of life in late-stage disease. In very late stages, dementia may complicate treatment, requiring discontinuation of combination therapy and use of low-dose levodopa with atypical neuroleptics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bennett DA, Beckett LA, Murray AM, et al.: Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996, 334:71–76.

    Article  PubMed  CAS  Google Scholar 

  2. Morens DA, Davis JW, Grandinetti A, et al.: Epidemiologic observations on Parkinson’s disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996, 46:1044–1050.

    PubMed  CAS  Google Scholar 

  3. Miyasaki JM, Martin W, Suchowersky O, Lang AE, Weiner JW: Practice parameter: initiation of treatment for Parkinson’s disease - an evidence based review. Neurology 2002, 58:11–17.

    Article  PubMed  CAS  Google Scholar 

  4. Miyawaki E, Lyons K, Pahwa R, et al.: Motor complications of chronic levodopa therapy in Parkinson’s disease. Clin Neuropharmacol 1997, 20:523–530.

    Article  PubMed  CAS  Google Scholar 

  5. Koller WC, Hutton JT, Tolosa E, Capilldeo R, and the Carbidopa / Levodopa Study Group: Immediate-release and controlled release carbidopa / levodopa in PD. Neurology 1999, 53:1012–1019.

    PubMed  CAS  Google Scholar 

  6. Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 1996, 39:37–45.

    Article  Google Scholar 

  7. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA: Levodopa induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord 1992, 7:117–124.

    Article  PubMed  CAS  Google Scholar 

  8. Nutt JC, Holford NH: The response to levodopa in Parkinson’s disease: imposing pharmocological law and order. Ann Neurol 1996, 39:561–573.

    Article  PubMed  CAS  Google Scholar 

  9. Djaldetti R, Baron J, Ziv I, Melamed E: Gastric emptying in Parkinson’s disease: patients with and without response fluctuations. Neurology 1996, 46:1051–1054.

    PubMed  CAS  Google Scholar 

  10. Bedard PJ, Blanchet PJ, Levesque D, et al.: Pathophysiology of L-Dopa-induced dyskinesias. Mov Disord 1999, 14(suppl 1):4–8. Good review of the proposed mechanisms resulting in dyskinesias.

    PubMed  Google Scholar 

  11. Chase TN, Engber TM, Mouradian MM: Contribution of dopaminergic and glutaminergic mechanisms to the pathogenesis of motor response complications in Parkinson’s disease. Adv Neurol 1996, 69:497–501.

    PubMed  CAS  Google Scholar 

  12. Chase TN, Engber TM, Mouradian MM: Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson’s disease. Neurology 1994, 44(suppl 6):S15-S18.

    PubMed  CAS  Google Scholar 

  13. Lieberman A, Olanow CW, Sethi K, et al.: A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Neurology 1998, 51:1057–1062.

    PubMed  CAS  Google Scholar 

  14. Lieberman A, Ranhosky A, Korts D: Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997, 49:162–168.

    PubMed  CAS  Google Scholar 

  15. Guttman M, for the International Pramipexole-Bromocriptime Study Group: Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 1997, 49:1060–1065.

    PubMed  CAS  Google Scholar 

  16. Hobson D, Lang AE, Martin WR, et al.: Excessive daytime sleepiness and sudden onset sleep in Parkinson’s disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, in press. Most recent and extensive study reporting the prevalence of excessive daytime somnolence and sleep attacks in Parkinson’s disease patients using a variety of dopaminergic medications. The authors conclude that use of the Epworth Sleepiness Scale in combination with Inappropriate Sleep Composite Score may be a sensitive method for predicting which patients are at risk for falling asleep when driving.

  17. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908–1910.

    PubMed  CAS  Google Scholar 

  18. Pal S, Bhattacharya KF, Agipito C, et al.: A study of excessive daytime sleepiness and its clinical significance in three group of Parkinson’s disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neurol Transm 2001, 108:71–77.

    Article  CAS  Google Scholar 

  19. Tan EK, Jankovic J: Choosing dopamine agonists in Parkinson’s disease. Clin Neuropharm 2001, 24:247–253. Excellent review of the available dopamine agonists, discussing the literature that addresses comparison studies.

    Article  CAS  Google Scholar 

  20. Hanna PA, Ratcos L, Ondo WG, et al.: A comparison of the therapeutic efficacy of pergolide and pramipexole in Parkinson’s disease. J Neurol Tansm 2001, 108:63–70.

    Article  CAS  Google Scholar 

  21. Parkinson Study Group: Entacapone improves motor fluctuations in levodopa treated Parkinson’s disease patients. Ann Neurol 1997, 42:747–755.

    Article  Google Scholar 

  22. Tolcapone Study Group: Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa treated parkinson’s patients. Mov Disord 1999, 14:38–44.

    Article  Google Scholar 

  23. Rinne UK, Larsen JP, Siden A, et al.: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998, 51:1309–1314.

    PubMed  CAS  Google Scholar 

  24. Suchowersky O, Bailey P, Pourcher E, Bulger L, Facciponte G: Comparison of two doses of tolcapone added to levodopa in nonfluctuating patients with PD. Clin Neuropharm 2001, 24:214–220.

    Article  CAS  Google Scholar 

  25. Holm KJ, Spencer CM: Entacapone. A review of its use in Parkinson’s disease. Drugs 1999, 58:159–177.

    Article  PubMed  CAS  Google Scholar 

  26. Assal F, Spahr L, Hadengue A, et al.: Tolcapone and fulminant hepatitis. Lancet 1998, 352:958.

    Article  PubMed  CAS  Google Scholar 

  27. Verhagen-Metman L, Dotto PD, LePoole K, et al.: Amantadine for levodopa-induced dyskinesias. A 1 year follow-up study. Arch Neurol 1999, 56:1383–1386.

    Article  Google Scholar 

  28. Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993, 328:176–183.

    Article  Google Scholar 

  29. Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996, 39:29–36.

    Article  Google Scholar 

  30. Goetz CG, Blasucci L, Stebbins GT: Switching dopamine agonists in advanced Parkinson’s disease. Is rapid titration preferable to slow? Neurology 1999, 52:1227–1229. This study looks at the pros and cons of doing a rapid versus slow changeover from one dopamine agonist to another, and concludes that a rapid switch is safe and effective.

    PubMed  CAS  Google Scholar 

  31. Gimenez-Roldan S, Esteban EM, Mateo D: Switching from bromocriptine to ropinirole in patients with advanced Parkinson’s disease: open label pilot responses to three different dose-ratios. Clin Neuropharm 2001, 24:346–351.

    Article  CAS  Google Scholar 

  32. Schwartz J, Arnold G, Gasser T, Hundemer HP: High-dose therapy with pergolide - results of a perspective, randomized study. Parkinsonism Rel Disord 2001, 7(suppl):S129.

    Article  Google Scholar 

  33. Bennett JP, Landow ER, Dietrick S, Schuh LA: Supression of dyskinesias in advanced Parkinson’s disease: Moderate daily clozapine does provide long-term dyskinesia reduction. Mov Disord 1994, 9:409–414.

    Article  PubMed  Google Scholar 

  34. Durif F, Vidailhet M, Bonnett AM, Blin J, Aagid Y: Levodopainduced dyskinesias are improved by fluoxetine. Neurology 1995, 45:1855–1858.

    PubMed  CAS  Google Scholar 

  35. Carpentier AF, Bonnett AM, Vildailhet M, Agid Y: Improvement of levodopa-induced dyskinesia by propranolol in Parkinson’s disease. Neurology 1996, 46:1548–1551.

    PubMed  CAS  Google Scholar 

  36. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G: Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994, 17:73–82.

    Article  PubMed  CAS  Google Scholar 

  37. Lang AE, Lozano AM: Parkinson’s disease, Second of Two Parts. N Engl J Med 1998, 339:1130–1143b.

    Article  PubMed  CAS  Google Scholar 

  38. Sage JI, Sonsalla PK, McHale DM, Heikkila RE, Duvoisin RC: Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson’s disease. Adv Neurol 1990, 53:383–386.

    PubMed  CAS  Google Scholar 

  39. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ: Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson’s disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996, 60:634–637.

    Article  PubMed  CAS  Google Scholar 

  40. Ondo W, Hunter C, Almaguer M, et al.: Sublingual apomorphine in patients with fluctuating Parkinson’s disease. Mov Disord 1999, 14:664–668.

    Article  PubMed  CAS  Google Scholar 

  41. Bozek C, Suchowersky O, Purves SJ, Calne S, Calne DB: Effect of protein intake on Sinemet efficacy. Clin Neuropharm 1986, 9:196–199.

    Article  CAS  Google Scholar 

  42. Berke GS, Gerrast B, Kreiman J, Jackson K: Treatment of parkinson hypothonia with percutaneous collagen augmentation. Laryngoscope 1999, 109:1295–1299.

    Article  PubMed  CAS  Google Scholar 

  43. Kannus P, Parkkari J, Niemi S, et al.: Prevention of hip fractures in elderly people with the use of a hip protector. N Engl J Med 2000, 343:15406–15413.

    Article  Google Scholar 

  44. Suchowersky O, Furtado S, Rohs G: Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 1995, 10:337–340.

    Article  PubMed  CAS  Google Scholar 

  45. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ: Treatment of erectile dysfunction with sildenafil (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypertension. J Neurol Neurosurg Psychiatry 2001, 71:371–374.

    Article  PubMed  CAS  Google Scholar 

  46. Dooneief G, Mirabello E, Bell K, et al.: An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992, 49:305–307.

    PubMed  CAS  Google Scholar 

  47. Sanno M, Stern Y, Williams J, et al.: Coexisting dementia and depression in Parkinson’s disease. Arch Neurol 1989, 46:1284–1286.

    Google Scholar 

  48. Richard IH, Kurlan R: A survey of antidepressant use in PD. Neurology 1997, 49:1168–1170.

    PubMed  CAS  Google Scholar 

  49. Dell’Angnello G, Ceravalo R, Nuti A, et al.: SSRIs do not worsen Parkinson’s disease: evidence from an open-label prospective study. Clin Neuropharm 2001, 24:221–227.

    Article  Google Scholar 

  50. Richard IH, Kurlan R, Tanner C, et al., for the Parkinson Study Group: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology 1997, 48:1070–1077.

    PubMed  CAS  Google Scholar 

  51. Saint-Cyr JA, Taylor AE, Lang AE: Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology 1993, 43(suppl 6):S47-S52.

    PubMed  CAS  Google Scholar 

  52. Klawans HL: Psychiatric side effects during the treatment of Parkinson’s disease. J Neurol Transm 1998, 27(suppl):117–122.

    Google Scholar 

  53. Pars MA, Bastani B: Quetiapine (Seroquel) in the treatment of psychosis in patients with PD. J Neuropsychiatry Clin Neurosci 1998, 10:216–219.

    Google Scholar 

  54. Factor SA, Friedman JH: The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997, 12:483–496.

    Article  PubMed  CAS  Google Scholar 

  55. Zoldan J, Friedberg G, Weizman A, Melamed E: Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson’s disease. Adv Neurol 1996, 69:541–544.

    PubMed  CAS  Google Scholar 

  56. Ford B, Lynch T, Greene P: Risperidone in Parkinson’s disease. Lancet 1994, 344:681.

    Article  PubMed  CAS  Google Scholar 

  57. Hurwitz TA, Calne DB, Waterman K: Treatment of dopaminomimetic psychosis in Parkinson’s disease with electroconvulsive therapy. Can J Neurol Sci 1988, 15:32–34.

    PubMed  CAS  Google Scholar 

  58. Mohr E, Mendis T, Grimes JD: Late cognitive changes in Parkinson’s disease with an emphasis on dementia. In Behavioral Neurology of Movement Disorders. Advances in Neurology, vol 65. Edited by Werner WJ and Lang AE. New York: Raven Press; 1995:97–113.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Movement Disorders Program, University of Calgary, Area 3, Health Sciences Centre, 3350 Hospital Drive NW, T2N 4N1, Calgary, Alberta, Canada

    Oksana Suchowersky MD, FRCPC, FCCMG

Authors
  1. Oksana Suchowersky MD, FRCPC, FCCMG
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suchowersky, O. Parkinson’s disease: Medical treatment of moderate to advanced disease. Curr Neurol Neurosci Rep 2, 310–316 (2002). https://doi.org/10.1007/s11910-002-0006-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-002-0006-5

Keywords

Search

Navigation